A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy (Q57911965)

Gonçalo J. L. Bernardes

1

0 references

Dario Neri

Dario Neri

7

0 references

Sabrina Trüssel

3

Sabrina Trüssel

0 references

Giulio Casi

2

Giulio Casi

0 references

author name string

Isabelle Hartmann

4

0 references

Kathrin Schwager

Angewandte Chemie International Edition

5

0 references

language of work or name

English

0 references

publication date

15 December 2011

0 references

published in

0 references

volume

51

0 references

issue

4

0 references

page(s)

941-944

0 references

cites work

Development trends for monoclonal antibody cancer therapeutics.

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Potent antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Targeted cancer therapy: conferring specificity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Antibody-based targeting of the tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Antibody drug-conjugates targeting the tumor vasculature: Current and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Chemical modification of proteins at cysteine: opportunities in chemistry and biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527

Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106527